PONTE VEDRA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced that its Board of Directors has appointed John. T. Treace, Chief Executive Officer and... Read More

PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced the presentation of updated interim data for the ALIGN3D™ and Mini3D™ Lapiplasty ®... Read More

PONTE VEDRA, Fla., March 25, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced new technology innovations featured at the 2025 American College of Foot and Ankle... Read More

PONTE VEDRA, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty ® Procedures, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent... Read More

PONTE VEDRA, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the fourth quarter and full year of 2024 after the... Read More

PONTE VEDRA, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases utilizing its SpeedAkin™ Anatomic Compression... Read More

PONTE VEDRA, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2024 results. Highlights:... Read More

PONTE VEDRA, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 43 rd Annual J.P. Morgan... Read More

PONTE VEDRA, Fla., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced the limited market release and first surgical cases utilizing the Percuplasty™ Percutaneous... Read More

PONTE VEDRA, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc . (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases utilizing SpeedPlate™ MicroQuad ™ implants. The... Read More

PONTE VEDRA, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases combining IntelliGuide™ PSI technology with the... Read More

PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced that Guy Guglielmino joined the Company as Chief Commercial Officer. In this new position,... Read More

PONTE VEDRA, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer,... Read More

PONTE VEDRA, Fla., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Revenue of... Read More

PONTE VEDRA, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer,... Read More

PONTE VEDRA, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today commented on the recently released Centers for Medicare & Medicaid Services (CMS) Calendar Year 2025... Read More

PONTE VEDRA, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc . (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced the limited market release of the Nanoplasty™ 3D Minimally Invasive Bunion Correction ™... Read More

PONTE VEDRA, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced that it will release financial results for the third quarter of 2024 after the close of... Read More

PONTE VEDRA, Fla., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced that it filed a lawsuit against Stryker Corporation and its subsidiary Wright Medical... Read More

PONTE VEDRA, Fla., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc . (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™... Read More

PONTE VEDRA, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer,... Read More

PONTE VEDRA, Fla., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc . ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Revenue of... Read More

PONTE VEDRA, Fla., July 18, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced that it will release financial results for the second quarter of 2024 after the close of... Read More

PONTE VEDRA, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer,... Read More

PONTE VEDRA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Revenue of... Read More

DALLAS and PONTE VEDRA, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- The Professional Pickleball Association (PPA) Tour and Treace Medical Concepts, Inc. (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced that Treace Medical has been named the first Medical... Read More

PONTE VEDRA, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer,... Read More

PONTE VEDRA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today... Read More

PONTE VEDRA, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced that it will release financial results for the first quarter of 2024 after the close of... Read More

Treace Further Expands Focus on Bunion Deformity Education by Sponsoring First-Ever National Bunion Day in the U.S. on April 16, 2024 Launches New “Future You” Patient Education and Brand Awareness Campaign PONTE VEDRA, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”)... Read More

PONTE VEDRA, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided... Read More

PONTE VEDRA, Fla., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc . (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced that it will release financial results for the fourth quarter and full year of 2023 after... Read More

PONTE VEDRA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ( “Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced three-year interim clinical data from its ALIGN3D™ post-market study supporting the use of... Read More

PONTE VEDRA, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced it will highlight new technology innovations and three-year interim ALIGN3D™ clinical... Read More

PONTE VEDRA, Fla., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2023 revenue results. Highlights:... Read More

PONTE VEDRA, Fla., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 42 nd Annual J.P. Morgan... Read More

PONTE VEDRA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty ® 3D Bunion Correction ® Procedure, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights: Revenue of... Read More

PONTE VEDRA, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty ® 3D Bunion Correction ® Procedure, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will... Read More

PONTE VEDRA, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty ® 3D Bunion Correction ® Procedure, today announced that it will release financial results for the third quarter of 2023 after the close of trading on Thursday,... Read More

PONTE VEDRA, Fla., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty ® 3D Bunion Correction ® Procedure, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™... Read More

PONTE VEDRA, Fla., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty ® 3D Bunion Correction ® Procedure, is pleased to announce the United States Patent and Trademark Office’s (USPTO) forthcoming issuance of U.S.... Read More

Further Expands Market Opportunity to Include Hammertoe Correction Company Receives 510(k) Clearance for Second-Generation SpeedPlate™ Implant Fixation Platform Ahead of Full Market Launch in Fourth Quarter of 2023 PONTE VEDRA, Fla., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment... Read More

PONTE VEDRA, Fla., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty ® 3D Bunion Correction™ Procedure, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will... Read More

PONTE VEDRA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty ® 3D Bunion Correction™ Procedure, today announced Nathan Minnich has been appointed Sr. Vice President, Marketing, effective immediately. In this... Read More

PONTE VEDRA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty ® 3D Bunion Correction™ Procedure, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights: Revenue of $42.0... Read More

PONTE VEDRA, Fla., July 24, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty ® 3D Bunion Correction™ Procedure, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will... Read More

PONTE VEDRA, Fla., July 18, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that it will release financial results for the second quarter of 2023 after the close of trading on Tuesday, August 8, 2023. Company management will host a conference call... Read More

PONTE VEDRA, Fla., July 12, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty ® 3D Bunion Correction™ Procedure, today announced that Julie Dewey will join the Company as Chief Communications and Investor Relations Officer,... Read More

PONTE VEDRA, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that it has completed its previously announced acquisition of certain assets from MIOS Marketing, LLC d/b/a RedPoint Medical3D (“RPM-3D”), a medical... Read More

PONTE VEDRA, Fla., June 01, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that it has signed an asset purchase agreement to acquire certain assets of MIOS Marketing, LLC d/b/a RedPoint Medical3D (“RPM-3D”), a medical technology... Read More

PONTE VEDRA, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the first quarter ended March 31, 2023. Recent Highlights: Revenue of $42.2 million in the first quarter of 2023, a 45% increase over... Read More

PONTE VEDRA, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will... Read More

PONTE VEDRA, Fla., April 20, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that it will release financial results for the first quarter of 2023 after the close of trading on Monday, May 8,... Read More

PONTE VEDRA, Fla., April 19, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), is pleased to announce the continuing rapid growth of its global patent portfolio. In 2023, Treace has filed 15 new United States patent applications and the United... Read More

PONTE VEDRA, Fla., April 04, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today published its inaugural Environmental, Social and Governance (ESG) report. This report highlights the Company’s strategic and ESG-related initiatives from the past... Read More

PONTE VEDRA, Fla., March 07, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights: Revenue of $49.8 million in the fourth quarter of 2022,... Read More

PONTE VEDRA, Fla., March 03, 2023 (GLOBE NEWSWIRE) - - Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) jointly announces with Fusion Orthopedics, LLC (“Fusion Orthopedics”) that they have reached an amicable resolution of the litigation between the parties. Treace... Read More

PONTE VEDRA, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on... Read More

PONTE VEDRA, Fla., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure today announced it will highlight new interim clinical data from the ALIGN3D™ study, and recent product innovations, at the 2023... Read More

PONTE VEDRA, Fla., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced the pricing of an underwritten public offering of 4,761,905 shares of its common stock at a public offering price... Read More

PONTE VEDRA, Fla., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. All of the... Read More

PONTE VEDRA, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced preliminary unaudited results for fourth quarter and full year 2022. Preliminary unaudited revenue... Read More

PONTE VEDRA, Fla., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will... Read More

PONTE VEDRA, Fla., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), is pleased to announce that the United States Patent and Trademark Office has granted to the Company U.S. Patent Nos. 11,497,528 and 11,523,845. The two new... Read More